Silodosin in the Management of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: An Experts Perspective Study
Abstract
Background: Benign prostatic hyperplasia (BPH) commonly causes lower urinary tract symptoms (LUTS), with α1-blockers as first-line therapy. Silodosin, due to its high uroselectivity and favorable tolerability, is increasingly used; this survey assesses clinician preferences, usage patterns, tolerability, and combination therapy practices in clinical practice. Methods: This cross-sectional survey was conducted among 97 urologists in India and used a validated 23-item questionnaire to assess treatment preferences, silodosin use, switching patterns, adverse events, combination therapies, and outcomes. Data were analyzed descriptively as frequencies and percentages. Results: The survey included 97 participants. A majority of clinicians (76%) preferred silodosin as the first-line α1-blocker for BPH management. Approximately 44% recognized all listed reasons for its use, including receptor selectivity, safety profile, and clinical benefits. Switching from tamsulosin to silodosin in 21–30% of patients due to inadequate symptom relief was reported by around 43% of clinicians. Marked clinical improvement with silodosin was observed by nearly 77%, while 54% reported no associated adverse drug reactions. Reduction in the risk of BPH-related surgery was identified as the key advantage of combination therapy by around 47% of clinicians. Preference for the silodosin and dutasteride combination to prevent disease progression was noted by 85% of respondents, and approximately 53% reported…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 97 participants or records.
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.